Areima^®

International nonproprietary name

Camrelizumab

Description

A monoclonal anti-PD-1 antibody, that reactivates tumor-specific cytotoxic T lymphocytes, and stimulates the anti-tumor immune response for the therapy of cancer.

Application

• Treatment of locally advanced or metastatic esophageal squamous cell carcinoma in combination with paclitaxel and cisplatin as 1st line therapy.
• As monotherapy for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma with disease progression after previous chemotherapy or intolerance to 1st line of therapy.
• Treatment for recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin as 1st line therapy.
• First-line treatment of locally advanced or metastatic non-squamous NSCLC without EGFR or ALK mutations in combination with pemetrexed and carboplatin.
• First-line treatment of locally advanced or metastatic squamous NSCLC in combination with paclitaxel and carboplatin.
• Triple-Negative Breast Cancer (TNBC). Areima in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer.